E. Ohman J or Asset Management AB Has $2.16 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

E. Ohman J or Asset Management AB cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.4% in the fourth quarter, Holdings Channel reports. The firm owned 24,184 shares of the medical equipment provider’s stock after selling 1,100 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Lantheus were worth $2,164,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the 3rd quarter worth about $25,000. Signaturefd LLC boosted its stake in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the last quarter. UMB Bank n.a. grew its holdings in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the period. GAMMA Investing LLC increased its stake in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 146 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus in the third quarter worth $51,000. Institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on LNTH shares. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Stock Up 2.5 %

Shares of LNTH opened at $91.80 on Wednesday. Lantheus Holdings, Inc. has a twelve month low of $52.96 and a twelve month high of $126.89. The stock has a market capitalization of $6.38 billion, a P/E ratio of 15.27 and a beta of 0.44. The company has a 50 day moving average of $92.07 and a 200-day moving average of $99.16.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.